Prediagnosis plasma adiponectin in relation to colorectal cancer risk according to KRAS mutation status

Kentaro Inamura, Mingyang Song, Seungyoun Jung, Reiko Nishihara, Mai Yamauchi, Paul Lochhead, Zhi Rong Qian, Sun A. Kim, Kosuke Mima, Yasutaka Sukawa, Atsuhiro Masuda, Yu Imamura, Xuehong Zhang, Michael N. Pollak, Christos S. Mantzoros, Curtis C. Harris, Edward Giovannucci, Charles S. Fuchs, Eunyoung Cho, Andrew T. ChanKana Wu, Shuji Ogino

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Low levels of adiponectin (ADIPOQ; HGNC ID; HGNC:13633), an adipokine, are associated with obesity, adiposity, excess energy balance, and increased risk of colorectal neoplasia. Given the reported association of increased body mass index (BMI) and low-level physical activity with KRAS-mutated colorectal tumor, we hypothesized that low-level plasma adiponectin might be associated with increased risk of KRAS-mutant colorectal carcinoma but not with risk of KRAS wild-type carcinoma. Methods: We conducted molecular pathological epidemiology research using a nested case-control study design (307 incident rectal and colon cancer case patients and 593 matched control individuals) within prospective cohort studies, the Nurses' Health Study (152 case patients and 297 control individuals, with blood collection in 1989-1990) and the Health Professionals Follow-up Study (155 case patients and 296 control individuals, with blood collection in 1993-1995). Multivariable conditional logistic regression models and two-sided likelihood ratio tests were used to assess etiologic heterogeneity of the associations. Results: The association of low-level plasma adiponectin with colorectal cancer risk statistically significantly differed by KRAS mutation status (Pheterogeneity= .004). Low levels of plasma adiponectin were associated with KRAS-mutant colorectal cancer (for the lowest vs highest tertile: multivariable odds ratio [OR] = 2.83, 95% confidence interval [CI] = 1.50 to 5.34, Ptrend = .002) but not with KRAS wild-type cancer (for the lowest vs highest tertile: multivariable OR = 0.83, 95% CI = 0.49

Original languageEnglish
Article numberdjv363
JournalJournal of the National Cancer Institute
Volume108
Issue number4
DOIs
Publication statusPublished - 2016
Externally publishedYes

Fingerprint

Adiponectin
Colorectal Neoplasms
Mutation
Logistic Models
Odds Ratio
Confidence Intervals
Adipokines
Molecular Epidemiology
Adiposity
Health
Rectal Neoplasms
Colonic Neoplasms
Case-Control Studies
Neoplasms
Body Mass Index
Cohort Studies
Obesity
Nurses
Prospective Studies
Exercise

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inamura, K., Song, M., Jung, S., Nishihara, R., Yamauchi, M., Lochhead, P., ... Ogino, S. (2016). Prediagnosis plasma adiponectin in relation to colorectal cancer risk according to KRAS mutation status. Journal of the National Cancer Institute, 108(4), [djv363]. https://doi.org/10.1093/jnci/djv363

Prediagnosis plasma adiponectin in relation to colorectal cancer risk according to KRAS mutation status. / Inamura, Kentaro; Song, Mingyang; Jung, Seungyoun; Nishihara, Reiko; Yamauchi, Mai; Lochhead, Paul; Qian, Zhi Rong; Kim, Sun A.; Mima, Kosuke; Sukawa, Yasutaka; Masuda, Atsuhiro; Imamura, Yu; Zhang, Xuehong; Pollak, Michael N.; Mantzoros, Christos S.; Harris, Curtis C.; Giovannucci, Edward; Fuchs, Charles S.; Cho, Eunyoung; Chan, Andrew T.; Wu, Kana; Ogino, Shuji.

In: Journal of the National Cancer Institute, Vol. 108, No. 4, djv363, 2016.

Research output: Contribution to journalArticle

Inamura, K, Song, M, Jung, S, Nishihara, R, Yamauchi, M, Lochhead, P, Qian, ZR, Kim, SA, Mima, K, Sukawa, Y, Masuda, A, Imamura, Y, Zhang, X, Pollak, MN, Mantzoros, CS, Harris, CC, Giovannucci, E, Fuchs, CS, Cho, E, Chan, AT, Wu, K & Ogino, S 2016, 'Prediagnosis plasma adiponectin in relation to colorectal cancer risk according to KRAS mutation status', Journal of the National Cancer Institute, vol. 108, no. 4, djv363. https://doi.org/10.1093/jnci/djv363
Inamura, Kentaro ; Song, Mingyang ; Jung, Seungyoun ; Nishihara, Reiko ; Yamauchi, Mai ; Lochhead, Paul ; Qian, Zhi Rong ; Kim, Sun A. ; Mima, Kosuke ; Sukawa, Yasutaka ; Masuda, Atsuhiro ; Imamura, Yu ; Zhang, Xuehong ; Pollak, Michael N. ; Mantzoros, Christos S. ; Harris, Curtis C. ; Giovannucci, Edward ; Fuchs, Charles S. ; Cho, Eunyoung ; Chan, Andrew T. ; Wu, Kana ; Ogino, Shuji. / Prediagnosis plasma adiponectin in relation to colorectal cancer risk according to KRAS mutation status. In: Journal of the National Cancer Institute. 2016 ; Vol. 108, No. 4.
@article{db46d9253b5f465ea42a4b001e2e65f3,
title = "Prediagnosis plasma adiponectin in relation to colorectal cancer risk according to KRAS mutation status",
abstract = "Background: Low levels of adiponectin (ADIPOQ; HGNC ID; HGNC:13633), an adipokine, are associated with obesity, adiposity, excess energy balance, and increased risk of colorectal neoplasia. Given the reported association of increased body mass index (BMI) and low-level physical activity with KRAS-mutated colorectal tumor, we hypothesized that low-level plasma adiponectin might be associated with increased risk of KRAS-mutant colorectal carcinoma but not with risk of KRAS wild-type carcinoma. Methods: We conducted molecular pathological epidemiology research using a nested case-control study design (307 incident rectal and colon cancer case patients and 593 matched control individuals) within prospective cohort studies, the Nurses' Health Study (152 case patients and 297 control individuals, with blood collection in 1989-1990) and the Health Professionals Follow-up Study (155 case patients and 296 control individuals, with blood collection in 1993-1995). Multivariable conditional logistic regression models and two-sided likelihood ratio tests were used to assess etiologic heterogeneity of the associations. Results: The association of low-level plasma adiponectin with colorectal cancer risk statistically significantly differed by KRAS mutation status (Pheterogeneity= .004). Low levels of plasma adiponectin were associated with KRAS-mutant colorectal cancer (for the lowest vs highest tertile: multivariable odds ratio [OR] = 2.83, 95{\%} confidence interval [CI] = 1.50 to 5.34, Ptrend = .002) but not with KRAS wild-type cancer (for the lowest vs highest tertile: multivariable OR = 0.83, 95{\%} CI = 0.49",
author = "Kentaro Inamura and Mingyang Song and Seungyoun Jung and Reiko Nishihara and Mai Yamauchi and Paul Lochhead and Qian, {Zhi Rong} and Kim, {Sun A.} and Kosuke Mima and Yasutaka Sukawa and Atsuhiro Masuda and Yu Imamura and Xuehong Zhang and Pollak, {Michael N.} and Mantzoros, {Christos S.} and Harris, {Curtis C.} and Edward Giovannucci and Fuchs, {Charles S.} and Eunyoung Cho and Chan, {Andrew T.} and Kana Wu and Shuji Ogino",
year = "2016",
doi = "10.1093/jnci/djv363",
language = "English",
volume = "108",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Prediagnosis plasma adiponectin in relation to colorectal cancer risk according to KRAS mutation status

AU - Inamura, Kentaro

AU - Song, Mingyang

AU - Jung, Seungyoun

AU - Nishihara, Reiko

AU - Yamauchi, Mai

AU - Lochhead, Paul

AU - Qian, Zhi Rong

AU - Kim, Sun A.

AU - Mima, Kosuke

AU - Sukawa, Yasutaka

AU - Masuda, Atsuhiro

AU - Imamura, Yu

AU - Zhang, Xuehong

AU - Pollak, Michael N.

AU - Mantzoros, Christos S.

AU - Harris, Curtis C.

AU - Giovannucci, Edward

AU - Fuchs, Charles S.

AU - Cho, Eunyoung

AU - Chan, Andrew T.

AU - Wu, Kana

AU - Ogino, Shuji

PY - 2016

Y1 - 2016

N2 - Background: Low levels of adiponectin (ADIPOQ; HGNC ID; HGNC:13633), an adipokine, are associated with obesity, adiposity, excess energy balance, and increased risk of colorectal neoplasia. Given the reported association of increased body mass index (BMI) and low-level physical activity with KRAS-mutated colorectal tumor, we hypothesized that low-level plasma adiponectin might be associated with increased risk of KRAS-mutant colorectal carcinoma but not with risk of KRAS wild-type carcinoma. Methods: We conducted molecular pathological epidemiology research using a nested case-control study design (307 incident rectal and colon cancer case patients and 593 matched control individuals) within prospective cohort studies, the Nurses' Health Study (152 case patients and 297 control individuals, with blood collection in 1989-1990) and the Health Professionals Follow-up Study (155 case patients and 296 control individuals, with blood collection in 1993-1995). Multivariable conditional logistic regression models and two-sided likelihood ratio tests were used to assess etiologic heterogeneity of the associations. Results: The association of low-level plasma adiponectin with colorectal cancer risk statistically significantly differed by KRAS mutation status (Pheterogeneity= .004). Low levels of plasma adiponectin were associated with KRAS-mutant colorectal cancer (for the lowest vs highest tertile: multivariable odds ratio [OR] = 2.83, 95% confidence interval [CI] = 1.50 to 5.34, Ptrend = .002) but not with KRAS wild-type cancer (for the lowest vs highest tertile: multivariable OR = 0.83, 95% CI = 0.49

AB - Background: Low levels of adiponectin (ADIPOQ; HGNC ID; HGNC:13633), an adipokine, are associated with obesity, adiposity, excess energy balance, and increased risk of colorectal neoplasia. Given the reported association of increased body mass index (BMI) and low-level physical activity with KRAS-mutated colorectal tumor, we hypothesized that low-level plasma adiponectin might be associated with increased risk of KRAS-mutant colorectal carcinoma but not with risk of KRAS wild-type carcinoma. Methods: We conducted molecular pathological epidemiology research using a nested case-control study design (307 incident rectal and colon cancer case patients and 593 matched control individuals) within prospective cohort studies, the Nurses' Health Study (152 case patients and 297 control individuals, with blood collection in 1989-1990) and the Health Professionals Follow-up Study (155 case patients and 296 control individuals, with blood collection in 1993-1995). Multivariable conditional logistic regression models and two-sided likelihood ratio tests were used to assess etiologic heterogeneity of the associations. Results: The association of low-level plasma adiponectin with colorectal cancer risk statistically significantly differed by KRAS mutation status (Pheterogeneity= .004). Low levels of plasma adiponectin were associated with KRAS-mutant colorectal cancer (for the lowest vs highest tertile: multivariable odds ratio [OR] = 2.83, 95% confidence interval [CI] = 1.50 to 5.34, Ptrend = .002) but not with KRAS wild-type cancer (for the lowest vs highest tertile: multivariable OR = 0.83, 95% CI = 0.49

UR - http://www.scopus.com/inward/record.url?scp=84964894113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964894113&partnerID=8YFLogxK

U2 - 10.1093/jnci/djv363

DO - 10.1093/jnci/djv363

M3 - Article

C2 - 26598515

AN - SCOPUS:84964894113

VL - 108

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4

M1 - djv363

ER -